Literature DB >> 8985787

NMR solution structure of the receptor binding domain of Pseudomonas aeruginosa pilin strain P1. Identification of a beta-turn.

A P Campbell1, H Sheth, R S Hodges, B D Sykes.   

Abstract

The solution structure of the peptide antigen from the receptor binding domain of Pseudomonas aeruginosa strain P1 has been determined using two-dimensional 1H NMR techniques. Ensembles of solution conformations for the trans form of this 23-residue disulfide bridged peptide have been generated using a simulated annealing procedure in conjunction with distance and torsion angle restraints derived from NMR data. Comparison of the NMR-derived solution structures of the P1 peptide with those previously determined for the 17-residue PAK, PAO and KB7 strain peptides [McInnes, C., et al. (1993) Biochemistry 32, 13432-13440; Campbell, A.P., et al. (1995) Biochemistry 34, 16255-16268] reveals the common structural motif of a beta-turn, which may be the necessary structural requirement for recognition of a common cell surface receptor and a common cross-reactive antibody to which all four strains bind. The importance of this conserved beta-turn in the PAK, PAO, KB7 and P1 peptides is discussed with regard to the design of a synthetic peptide vaccine effective against multiple strains of Pseudomonas aeruginosa infections.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8985787     DOI: 10.1111/j.1399-3011.1996.tb00873.x

Source DB:  PubMed          Journal:  Int J Pept Protein Res        ISSN: 0367-8377


  2 in total

1.  Advantages of a synthetic peptide immunogen over a protein immunogen in the development of an anti-pilus vaccine for Pseudomonas aeruginosa.

Authors:  Daniel J Kao; Robert S Hodges
Journal:  Chem Biol Drug Des       Date:  2009-07       Impact factor: 2.817

2.  Animal protection and structural studies of a consensus sequence vaccine targeting the receptor binding domain of the type IV pilus of Pseudomonas aeruginosa.

Authors:  Daniel J Kao; Mair E A Churchill; Randall T Irvin; Robert S Hodges
Journal:  J Mol Biol       Date:  2007-09-19       Impact factor: 5.469

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.